Capricor Therapeutics (NASDAQ:CAPR) announced its quarterly earnings results on Wednesday. The biotechnology company reported ($0.34) EPS for the quarter, meeting the Zacks’ consensus estimate of ($0.34), MarketWatch Earnings reports. The company had revenue of $0.22 million for the quarter, compared to analysts’ expectations of $0.07 million. Capricor Therapeutics had a negative net margin of 761.69% and a negative return on equity of 237.36%.
Capricor Therapeutics stock opened at $1.11 on Friday. The firm’s fifty day moving average price is $1.28 and its 200-day moving average price is $1.89. The stock has a market cap of $4.72 million, a P/E ratio of -0.51 and a beta of 2.16. Capricor Therapeutics has a fifty-two week low of $0.88 and a fifty-two week high of $8.85.
A number of analysts recently commented on the stock. Zacks Investment Research upgraded shares of Capricor Therapeutics from a “hold” rating to a “strong-buy” rating and set a $2.00 price target on the stock in a research note on Thursday, January 23rd. ValuEngine upgraded shares of Capricor Therapeutics from a “hold” rating to a “buy” rating in a research note on Friday, January 3rd. HC Wainwright reiterated a “buy” rating and issued a $9.00 target price on shares of Capricor Therapeutics in a research note on Thursday. Finally, Maxim Group reiterated a “buy” rating and issued a $4.00 target price on shares of Capricor Therapeutics in a research note on Friday.
Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.
Featured Story: Overbought
Receive News & Ratings for Capricor Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capricor Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.